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Abstract: Summary In this cohort of community dwelling older adults (>60 yrs), we observed
significant positive associations between the frequency of yogurt intake and bone
health.
Introduction The associations of yogurt intakes with bone health and  frailty in older
adults are not well documented. The aim was to investigate the association of yogurt
intakes with bone mineral density [BMD)], bone biomarkers and physical function in
4,310 Irish adults from the Trinity, Ulster, Department of Agriculture aging cohort study
(TUDA).
Methods Bone measures included total hip, femoral neck and vertebral BMD with bone
biochemical markers. Physical function measures included Timed Up and Go (TUG),
Instrumental Activities of Daily Living Scale and Physical Self-Maintenance Scale.
Results Total hip and femoral neck BMD in females were 3.1 - 3.9 % higher among
those with the highest yogurt intakes (n= 970) compared to the lowest (n= 1,109; P
<0.05) as were the TUG scores (-6.7%; P = 0.020). In males, tartrate-resistant acid
phosphatase (TRAP 5b) concentrations were significantly lower in those with the
highest yogurt intakes (-9.5%; P <0.0001). In females, yogurt intake was a significant
positive predictor of BMD at all regions. Each unit increase in yogurt intake in females
was associated with a 29% lower risk of osteopenia (OR 0.71; 95% CI 0.51 - 1.01;
P=0.037) and a 37% lower risk of osteoporosis (OR 0.63; 95% CI 0.44 - 0.91; P=0.014)
and in males, a 51% lower risk of osteoporosis (OR 0.49; 95% CI 0.25 - 0.94;
P=0.032).
Conclusion In this cohort, higher yogurt intake was associated with increased BMD and
physical function scores. These results suggest that improving yogurt intakes could be
a valuable and cost-effective health strategy for maintaining bone health in older
adults.
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Dear Co-Editors,
We would be very grateful if you would consider our manuscript "Greater yogurt
consumption is associated with increased bone mineral density (BMD) and physical
function in older adults" for publication in Osteoporosis International
Osteoporosis is an increasingly common, chronic condition estimated to affect over
200 million individuals worldwide. Maintaining an optimal nutritional status is a key
preventative measure, particularly for older adults (>60 years). Of the major food
groups, dairy foods (including milk, yogurt and cheese) are one of the richest sources
of the macro and micro nutrients that contribute to bone health. There is however, little
information on the associations of yogurt intake, with BMD and bone health bio-
markers in addition to concomitant measurements of physical function in this older
population.
In this study we investigate the associations of daily dairy intakes (in particular yogurt)
and the associations with BMD, bone biomarkers and measures of physical function in
4,310 older adults (60-102 years). The participants were originally recruited to the
Trinity Ulster Department of Agriculture (TUDA) aging cohort study, a large study of
older Community dwelling Irish adults designed to investigate nutritional factors and
gene-nutrient interactions in the development of chronic diseases of aging. Data for the
current study relate to >4,000 participants, making it the largest study to-date
examining yogurt intakes and associations with bone health and frailty. Bone
biomarkers included serum osteocalcin, Bone specific alkaline phosphatase, C-
terminal telopeptides of type I collagen and Tartrate-resistant acid phosphatase (TRAP
5b). BMD was measured at the total hip, femoral neck and vertebral spine. Physical
function measures included Timed get Up and Go and the Instrumental Activities of
Daily living scale. Total hip and femoral BMD in women were 3.1 - 3.9 % higher
amongst those with the highest yogurt intakes, as were the TUG scores (-6.7%). TRAP
5b concentrations were significantly lower in men with the highest yogurt intakes (-
9.5%). In a regression model examining predictors of osteoporosis, each unit increase
in daily yogurt intake was associated with a 29% lower risk of osteopenia and a 37%
lower risk of osteoporosis in women ( what about osteopenia in men) and a 51% lower
risk of osteoporosis in men
Our findings provide evidence that an increase in the frequency of yogurt intake is
positively associated bone health status and measurements of physical function in a
cohort of older adults. We believe the findings of the current study will contribute
significantly to the growing evidence supporting a beneficial role for yogurt in health.
Thank you for taking the time to consider this manuscript.
Yours sincerely,
Dr Eamon Laird
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Research Fellow, Trinity College Dublin, Ireland
Response to Reviewers: Reviewer 1
This is a well written observational cross-sectional study carried out in a large cohort of
community dwelling older (>60 years) females and male subjects.
Response: We thank reviewer 1 for their helpful comments regarding the manuscript.
The clarifications suggested by the reviewer are welcomed and the specific replies to
each comment are shown below.
1. My main concern is the excess of reliance on statistical analysis without considering
the pathophysiological relevance of the significance as computed by using various
tests including hierachical regression models with adjustement for about 15 variables.
For instance, what is the biological meaning of reporting that an increase in serum
25OHD is associated with greater (Odd ratio: 1.0, 95%CI 1.00-1.02 !) risk of
osteoporosis with a probability level of <0.0001 (Table 5) ? This kind of significance
test amalgamates precision with effect size, thus muddling two essential aspects of
data interpretation. A weak association between an extremely mild increase in serum
25OHD and the risk of osteoporosis is incorrectly interpreted as “important“ because it
is statistically significant. In order to control Type I error rate (i.e. to conclude there is a
difference though none exists) when multiple hypothesis are tested, a correction has to
be applied. Among several statistical correction tools, the Bonferroni correction is often
used, making it more difficult to reject the null hypothesis.
Response: We agree with the reviewer that this is an unexpected result and that we
should have mentioned this in the text (we did not discuss this in the results or
discussion). We feel this unexpected result could be due to the fact we did not include
those on vitamin D supplements as a variable in the multinomial regression model. We
have now included this for both women and men (Tables 5 and 6). Serum 25(OH)D is
no longer a significant predictor of bone health for women or men. However, yes to
vitamin D supplements is now a significant predictor of bone health. For women, those
on vitamin D supplements had a significantly reduced risk of osteopenia (OR 0.51;
95% CI 0.34 – 0.76; P=0.001) and a significantly reduced risk of osteoporosis (OR
0.41; 95% CI 0.26 – 0.64; P<0.0001). For men, those on vitamin D supplements also
had a significantly reduced risk of osteoporosis (OR 0.40; 95% CI 0.22 – 0.72;
P=0.003). These results have been added both to Tables 5 and 6. With the addition of
the vitamin D supplement variable to the model, the positive effect of daily yogurt
intakes on reducing the risk of impaired bone health has also increased (lines 246-
248).
In regards to the Bonferroni correction, the authors feel that it is statistically
inappropriate for the multinomial regression model as each variable included is
controlling for the other. However, for the other analysis (Tables 2-3 and Supplemental
Tables 2-3) we have used the Bonferroni correction. We apologise that this was not
made clear in the statistical methods and we have now added a sentence to this effect
and a footnote to each of the appropriate Tables. It is important to note however, that in
doing the Bonferroni correction, the correction directly targets the Type 1 error
problem, but it does so at the expense of Type 2 error. By changing the p value
needed to reject the null (or equivalently widening the uncertainty intervals) the number
of claims of rejected null hypotheses will indeed decrease on average. Although this
reduces the number of false rejections, it also increases the number of instances that
the null is not rejected when in fact it should have been. Thus, the Bonferroni correction
can severely reduce our power to detect an important effect (Gelman et al 2012).
2. According to DXA-BMD measurements (presumably by using either Total Hip or
Femoral Neck BMD? This referenced skeletal site has to be clearly indicated), odd
ratios were calculated for 15 variables in each gender (Tables 5 and 6). In females, 3
and 5 variables were found to be significantly associated with the risk of osteopenia
(+Age, -BMI, -Daily Yogurt Serving) and osteoporosis (+Age, -BMI, +25OHD, -Daily
Yogurt Serving), respectively. In males, 3 variables were found to be significantly
associated with the risk of osteopenia (-BMI, +Daily Cheese Serving, -Daily Meat
Serving) and osteoporosis (-BMI, -Daily Yogurt Serving, +Daily Cheese), respectively.
Some of these associations appear to be significant statistically, but without any
biological significance. Thus, in females mean serum 25OHD varies very little among
the 3 groups categorized according to the frequency of yogurt intakes (Table 2).
Similarly minimal variations of serum 25OHD were recorded in females distributed
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according to the frequency of milk (Supplemental Table 2) and cheese (Supplemental
Table 4) intakes.
Response: We have now inserted a sentence explaining the referenced skeletal sites
for Tables 5 and 6 as a footnote on each. In response to the results of the multinomial
regression model, some of the results that were observed were expected and have
been reported extensively in the literature (e.g. increasing age, and lower BMI
associated with increased risk of osteopenia/osteoporosis). We feel it is interesting
some of the dietary components were also significant as few studies often examine
these as predictors of bone health and thus little is known on the effects of diet on bone
health. As stated in response to query 1, the multinomial regression model is a robust
statistical model with each variable acting as a control/adjustment for another. In
regards to Table 2, supplemental Tables 2 and 4 it is actually a positive that 25(OH)D
concentrations did not differ between the groups as it can then be ruled out as a
potential likely driver of any effects on bone health that we observed.
3. To determine the predictors of bone fragility (osteopenia and osteoporosis) a
multinomial logistic regression model was used (with normal bone health as the
reference category) with relevant co-predictors including serum 25OHD as a nominal
variable (P.8, lines 184-190). As presented in Table 5, in females the risk of
osteoporosis would be positively increased by 1.01 (95% CI 1.00-1.02, P<0.0001) by
an augmentation of serum 25OHD. This is an example of highly statistical significance
without any pathophysiological significance. This kind of statistic test mixes effect size
and precision, thus muddling two essential aspects of data interpretation. Confidence
intervals provide both an estimate of the effect size and the precision of the
measurement.
Response: We have amended these results as explained in the response to queries 1,
2 and 6.
4. P.7, lines 168-169. References should be given for the functionality measures by
PSM and IADL.
Response: A reference has now been inserted (line 176).
5. P.8, line183-184. BMD unit is in gram of hydroxyapatite equivalent divided by the
DXA-scanned surface (g/cm2) of the region of interest. Therefore it does not
correspond to a “concentration“. This wrong unit designation should be corrected.
Response: We have now removed any mention of ‘concentration’ to BMD measures or
results in the manuscript.
6. Table 5. Females statistical analysis. Increasing age significantly augments the Odd
ratio (augments the risk) for both osteopenia (1.03 |1.00-1.06| P=0.043) and
osteoporosis (1.04 |1.01-1.08| P=0.008) (Table 5). Increasing BMI (0.92 |1.00-1.06|
P<0.0001). Physical activity and Yogurt consumption reduces the Odd ratio (reduces
the risk) of osteoporosis (Table 5). These findings are consistent with previous
knowledge on the risk factors of bone fragility in later age. A discordant finding
concerns bone fragility (osteopenia, osteoporosis) related to the vitamin D status. It is
reported that an increase in serum 25OHD rises the risk of osteoporosis (Table 5). This
is inconsistent with most published studies providing evidence that increasing vitamin
D status, as assessed by measuring the serum level of 25OHD,  reduces bone
turnover in menopausal women and is associated with a lower risk of fragility fractures
with aging.
Response: We have agree with the reviewer and have amended these results as
explained in the response to queries 1, 2 and 3.
7. -Table 6. Males statistical analysis. Increased BMI significantly reduces the Odd
ratio for osteoporosis. Increase in both yogurt and meat consumption also reduces the
risk of osteopenia and osteoporosis. These findings corroborate several published
results. In contrast, in this epidemiological study an increased consumption of cheese
would augment the risk of developing either osteopenia or osteoporosis. The authors
recognize that this statistical finding is in contradiction with recent reports indicating
that an increase of cheese consumption exerts a rather bone-protective effect. They
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
mention the hypothesis that a high sodium content of certain varieties of cheese would
increase the urinary excretion of calcium and, thereby, would negatively influence bone
mineral balance. However, the sodium-induced calciuria hypothesis is not supported
by any long term observations. To mention an untenable mechanistic hypothesis to
account for a statistically unexpected and contradictable result lowers the scientific
quality of the discussion.
Response: We acknowledge the reviewers comments the sodium-induced calciuria
hypothesis is not supported by any long term observations (e.g. the recent Women’s
Health initiative Study) and we have mentioned this in the text. However we also
recognize that this could offer a potential hypothesis to explain our observed results
and given that it has not been extensively examined in the literature, in particular for
the effects on men, we feel we must mention it as a possibility.
8. P.8, lines 195 - P9, line 196. The sentence “The majority of participants were
females, who were significantly older, lighter, and contained a higher proportion of
individuals receiving bone, vitamin D or calcium supplements in comparison with
males.“ is not clear. The word “bone“ should be deleted.
Response: We have deleted this from the sentence.
9. P.9, lines 220 – P10, lines 221-223. The differences highlighted in terms of milk
consumption, for Time up and Go, IADL and PSM (Supplemental Table 2 and 3, not
Suppl.Tables 1 and 2) are, though statistically significant, of trivial biological
significance. A more stringent statistical analysis using a multple-comparison
procedure (e.g. Bonferroni’s method) that increases the critical F or t is needed for
declaring the comparison to be significant.
Response: As stated in response to query 1, these results are adjusted for Bonferroni.
We again apologize for not making this clear in the manuscript and have added this as
a footnote to the Tables of interest.
10. P.10, line 224. Please substitute Supplemental Table 3 and 4 by Supplemental
Table 4 and 5.
Response: We have now switched these Supplemental Tables.
11. -Table 2 and Table 3. Reference range of the listed biochemical markers (CTX,
OC, BAP; TRAP 5b, 25OHD and PTH) should be indicated in the legend to these two
tables.
Response: We have now added these reference ranges in the methods section and in
the legends to Table 2 and 3.
12. P.10, lines 244-245 and P.11, lines 246-247. In men, Table 6 does not corroborate
the statement that in men increased yogurt consumption was associated with a
significant decrease in the Odd ratio of osteopenia (Table 6, 0.85, 95% CI 0.58-1.24, P
=0.410).
Response: We apologize for this error and have now amended the sentence.
13. P.11, lines 256-259. The reference #22 (Hochberg et al., 2002 J Clin Endocrinol
Metab) is a meta-analysis of randomized placebo-controlled trials in postmenopausal
women who were all diagnosed at baseline as being osteoporotic. The effects of
antiresorptive pharmaceutical agents (particularly the bisphosphonates alendronate
and risedronate) were analyzed regarding the later incidence of nonvertebral fractures
in relation with early changes in BMD and biochemical markers (BCM). This important
meta-analysis estimated that a 3% increase in hip BMD reduced nonvertebral fracture
risk by about 46%, and a 70% decrease in resorption BCM reduced nonvertebral
fracture risk by about 40 %. In contrast, the submitted observational cross-sectional
study was carried out in less than 60 % of osteoporotic women (360/626=57.5%, Table
5). Therefore, the hypothesis that the effects of increased yogurt consumption on BMD
and resorption biochemical markers would cause in the long term such a large
reduction in nonvertebral fracture risk should be expressed with some caution.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Response: We thanks the reviewer for this comment and have inserted this information
into the text and we have also stated that such a reduction is expressed with caution
‘However it is important to note that the meta-analysis [27] was conducted in women all
diagnosed with osteoporosis whereas in the current study only 60% of the women
were osteoporotic and thus the potential for yogurt to reduce fractures at the same rate
should be viewed with caution’ (lines 273-276).
14. The punctuation should be checked throughout the manuscript, particularly some
full stops are missing e.g.: P13, line 302.
Response: We apologize for this error and have now checked and amended the
manuscript throughout.
References
Gelman, Andrew, Jennifer Hill, and Masanao Yajima. "Why we (usually) don't have to
worry about multiple comparisons." Journal of Research on Educational Effectiveness
5.2 (2012): 189-211.
Reviewer 2:
In this cross-sectional study conducted in a large cohort of healthy men and women
aged 60 years and older, an association between bone health and physical function,
and yogurt consumption was assessed. The results indicate some positive association,
and suggest the possibility of yogurt based preventive regimens for maintaining bone
health. This paper raises the following comments.
Response: We thank reviewer 2 for their valuable comments regarding the manuscript.
The clarifications suggested by the reviewer are again highly appreciated and the
specific replies to each comment are shown below.
Major points:
1. The level of physical activity in yogurt consumers and non-consumers should be
presented.
Response: We have now added the sentence ‘In yogurt consumers, the proportion
who answered yes to physical activity was 80.9% while in non-consumers it was
74.7%.’ (lines 207-208).
2. The size of yogurt servings as well as whether yogurts are usually enriched in milk
powder in the region should be specified, in other words, whether 120 g of yogurt are
providing more calcium and protein than 120 g of milk.
Response: We have no data in relation to the serving size of each dairy type or the
particular product brand (lines 136 - 137) and thus we cannot state whether there is a
difference in the calcium or protein content. We have mentioned this as a limitation of
the study (lines 355-358). However, we have also mentioned the average serving
intake size of milk, yogurt and cheese in a representative study of older Irish adults
(>65 yrs) recruited at the same time period (as part of the National Adult Nutrition
Study (NANs) (lines 137 - 140).
3. The results should also be adjusted for calcium and protein of dairy origin, to
address the issue of yogurt specificity.
Response: As stated in our response to major point 2, we have no data in relation to
the serving size of each dairy type or the particular product brand and thus we cannot
adjust for the exact protein or calcium amount of dairy origin. However, through all of
the analysis of the associations of yogurt with BMD and bone health we have adjusted
for the frequency of intakes for other dairy products such as milk and cheese and have
adjusted for the frequency of intakes for non-dairy products including red and white
meat (total meat), oily and white fish (total fish) and egg intakes.
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4. What would be the results when adjusted for weight and height, instead of BMI?
Response: We have repeated the analysis with adjustment for weight and height
instead of BMI and the results are very similar to what has been reported in the
manuscript. For women, total hip BMD was 3.1% higher (P=0.004) and the femoral
neck BMD was 3.9% higher (P<0.0001) in those with the highest yogurt intakes
compared to the lowest. All other results for women were also similar. For men, the
concentrations of the bone biomarker TRAP were 9.6% lower in those with the highest
yogurt intakes compared to the lowest (P=0.004).
5. The associations differ between men and women. What kind of explanation can be
provided?
Response: The results differ significantly between genders and we suggested that
given significantly fewer men than women were high yogurt consumers, it is possible
that there were only subtle bone turnover changes in men as not enough yogurt was
being consumed to affect BMD but enough to affect bone turnover (lines 283 - 286).
However, it is beyond the scope of the current study to detect the reason behind the
gender differences.
5. Did T-score differ between groups as well, without or with adjustment?
Response: For women only (without adjustment), total hip T-scores were significantly
higher (P=0.006) as were femoral neck T-scores (P<0.0001) in those with the highest
yogurt intakes compared to the lowest/none yogurt intake group. For women only (with
adjustment), total hip T-scores were significantly higher (P=0.004) as were femoral
neck T-scores (P<0.0001) in those with the highest yogurt intakes compared to the
lowest/none yogurt intake group. There was no difference in vertebral T-scores with or
without adjustment.
For men only, vertebral T-scores were significantly higher in the low yogurt consumer
group compared with the lowest/none yogurt intake group with adjustment (P =0.028)
and without adjustment (P=0.040). There was no differences in total hip or femoral
neck T-scores with or without adjustment.
Minor points
1. Abstract: cost-effectiveness of yogurt consumption has not been evaluated nor
discussed in the paper.
Response: This statement has been removed from the abstract
2. Introduction: the paper showing reduced fracture risk and mortality with fermented
dairy products may be quoted.
Response: This reference has now also been mentioned in the introduction (lines 92 -
93).
3. Did the subjects without BMD measurements differ from those included in the
present study?
Response: The TUDA study was based on three diseased cohorts: hypertension,
cognitive dysfunction and osteoporosis. Those who were on current bone treatment
were removed from the analysis. Subjects in the cognitive cohort (this cohort did not
have BMD measures) were recruited from geriatric clinics and a day hospital service
and cognitive impairment was assessed based on testing with the RBANS (Repeatable
Battery for the Assessment of Neuropsychological Status). This cohort was significantly
older and their ability to accurately recall dietary intakes may be compromised.
4. Which database was used to calculate T-score in men? The same as for women?
Response: The database used was from NHANES III for the femoral neck and total hip
and the manufacturer’s own database for the vertebral.
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5. Prevalent fracture should be reported
Response: A very small proportion of the cohort self-reported either a hip fracture (n =
54) or self-reported a vertebral fracture (n = 128) and thus we could not examine the
associations with dairy intakes as the study was not powered to detect or examine
prevalent fracture rates. Additionally, we cannot ensure the accuracy of these fractures
rates as they have been self-reported.
6. Phosphate supplements are very unusual. What was the reason for these 6%?
Response: We agree with the reviewer that phosphate supplements on their own is
quite unusual. However, the TUDA study collected information on all
supplements/medications consumed and thus an exhaustive search was conducted for
any preparation, medication or supplement that contained any phosphate to be as
thorough as possible.
7. P 11: the paper by Hochberg et al cannot be used in the present discussion since
the changes in BMD were achieved with pharmacological agents. There is no
argument that the relationship may be similar with nutritional intervention.
Response: We acknowledge the reviewers comments and although the changes in
BMD were achieved with pharmacological agents in the paper by Hochberg et al.,
there is still a possibility that there is a similar relationship with nutritional intervention
(dairy products) as this has not been investigated before. However we have modified
this part of the discussion in line with suggestions with reviewer 1 and have stated that
these possibilities should be treated with caution until further evidence is available.
8. The possibility that yogurt consumption may be a marker of a healthy lifestyle should
be discussed.
Response: We agree with the reviewer that yogurt consumption may be a marker of a
healthy lifestyle and have discussed this in the manuscript (lines 315 - 316).
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Mini-Abstract 24 
In this cohort of community dwelling older adults (>60 yrs), we observed significant positive 25 
associations between the frequency of yogurt intake with measures of bone density, bone 26 
biomarkers and indicators of physical function. Improving yogurt intakes could be a valuable 27 
health strategy for maintaining bone health in older adults. 28 
 29 
Abstract 30 
Introduction The associations of yogurt intakes with bone health and frailty in older adults are 31 
not well documented. The aim was to investigate the association of yogurt intakes with bone 32 
mineral density [BMD], bone biomarkers and physical function in 4,310 Irish adults from the 33 
Trinity, Ulster, Department of Agriculture aging cohort study (TUDA). 34 
Methods Bone measures included total hip, femoral neck and vertebral BMD with bone 35 
biochemical markers. Physical function measures included Timed Up and Go (TUG), 36 
Instrumental Activities of Daily Living Scale and Physical Self-Maintenance Scale.  37 
Results Total hip and femoral neck BMD in females were 3.1 - 3.9 % higher among those with 38 
the highest yogurt intakes (n= 970) compared to the lowest (n= 1,109; P <0.05) as were the 39 
TUG scores (-6.7%; P = .013). In males, tartrate-resistant acid phosphatase (TRAP 5b) 40 
concentrations were significantly lower in those with the highest yogurt intakes (-9.5%; P 41 
<0.0001). In females, yogurt intake was a significant positive predictor of BMD at all regions. 42 
Each unit increase in yogurt intake in females was associated with a 31% lower risk of 43 
osteopenia (OR 0.69; 95% CI 0.49 – 0.96; P=0.032) and a 39% lower risk of osteoporosis (OR 44 
0.61; 95% CI 0.42 - 0.89; P=0.012) and in males, a 52% lower risk of osteoporosis (OR 0.48; 45 
95% CI 0.24 - 0.96; P=0.038).   46 
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physical function scores. These results suggest that improving yogurt intakes could be a 48 
valuable public health strategy for maintaining bone health in older adults. 49 
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Introduction 72 
Osteoporosis is an increasingly common, chronic condition estimated to affect over 200 million 73 
individuals worldwide [1] with 6% of men and 21% of women aged 50-84yrs affected in the 74 
EU alone [2]. It is characterized by decreased bone mineral density (BMD) with a significantly 75 
increased risk of fracture and subsequently, morbidity and mortality [3]. The condition has 76 
been estimated to cause over 8.9 million fractures annually, with osteoporotic fractures 77 
accounting for 0.8% of the global burden of non-communicable disease and the loss of over 78 
5.8 million disability-adjusted life years (DALYs) [4-6].  79 
 80 
The development of osteoporosis can be influenced by a range of both demographic and 81 
lifestyle factors [1,7,8]. However, maintaining an optimal nutritional status is also a key 82 
preventative measure, particularly for older adults (>50 years) [9]. Of the major food groups, 83 
dairy foods are one of the richest sources of the macro and micro nutrients that contribute to 84 
bone health such as protein, calcium, magnesium and the B-vitamins [10-14]. For example, 85 
dairy products are the primary source of calcium across most industrialized countries in Europe 86 
and the USA [11,12]. Previous data from observational studies and randomized controlled trials 87 
(RCTs) have reported significant positive associations between dairy intakes and bone health 88 
as reviewed in recent commentaries and Government reports [15,16]. In one 12-yr follow-up 89 
analysis of the Framingham Offspring Study (n= 2,506; mean age 55 yrs), yogurt intake alone 90 
was positively associated with hip trochanter BMD and had a weak protective trend with hip 91 
fracture reduction [17].  Furthermore, fermented milk products have been associated with a 92 
lower fracture incidence and mortality [18]. There is however, little information on the 93 
associations of yogurt intake with bone health bio-markers and with measures of functionality. 94 
In the current study, we examined the association of yogurt intakes with BMD, biochemical 95 
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markers of bone health and physical function measures in a large cohort of free-living older 96 
adults (n= 4,310, age range 60-102 yrs). 97 
 98 
Subjects and Methods    99 
Data analyzed for the current study originated from the Trinity Ulster Department of Agriculture 100 
(TUDA) ageing cohort study, a large study of older Irish adults (>60 yrs) designed to investigate 101 
nutritional factors, related gene-nutrient interactions and a range of health and lifestyle factors 102 
in the development of chronic diseases of aging. Further details of sampling and recruitment 103 
have been described previously [19-22]. Of the 5,186 participants recruited, 3 with severe frailty 104 
(replied no or had a missing answer to the self-feeding question in the Physical Self-105 
Maintenance questionnaire (PSM)), 866 with cognitive impairment (Mini-Mental State 106 
Examination (MMSE) score <25) and those with a missing response to the yogurt intake 107 
question (n= 7) were excluded from the physical function analysis leaving a total of 4,310 108 
participants (Supplemental Figure 1). Approximately 1,699 participants did not have BMD 109 
measures taken. In addition to these exclusions, participants who reported receiving medications 110 
that could affect bone mineral metabolism (Bisphosphonates; Aromatase Inhibitors; 111 
Gonadotropin releasing hormone analogues or Luteinizing hormone releasing agonists; Anti-112 
androgen medication; Parathyroid hormone (PTH) treatment; Strontium treatment; Anti-113 
epileptic medications; Paget’s disease treatment) were also excluded from the BMD and bone 114 
biomarker analysis (Supplemental Figure 1). Ethical approval was granted by the relevant 115 
authorities in each jurisdiction: the Research Ethics Committee of St. James’s Hospital and The 116 
Adelaide and Meath Hospital, Dublin, and the Office for Research Ethics Committees Northern 117 
Ireland (ORECNI; reference 08/NI/RO3113) with corresponding approvals from the Northern 118 
and Western Health and Social Care Trusts, Northern Ireland. 119 
 120 
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Lifestyle and medications 121 
Data associated with lifestyle factors were obtained by questionnaire. Information included 122 
gender, age, ethnicity, physical activity (reported as yes/no in the last two weeks), smoking 123 
status and alcohol intake. Full details of dietary supplement and vitamin use including dose, 124 
frequency and duration was confirmed from packaging or prescription information. A small 125 
number of supplements listed were unidentifiable or contained unidentifiable ingredients; 126 
individuals consuming such supplements were excluded from analysis.  127 
 128 
Dietary dairy intake servings 129 
Participants were given a modified food frequency questionnaire (FFQ) which asked if the 130 
participant consumed yogurt, milk (approximated as glasses of milk per day) and/or cheese and 131 
if yes, how often for each dairy type. The total frequency of the daily intake serving for yogurt, 132 
milk and cheese was calculated from the FFQ responses (Supplemental Table 1). These values 133 
were then separated into tertiles of non-consumers, low consumers and high consumers for 134 
each dairy type. Information was also recorded for the frequency of consumption of red meat 135 
and poultry (total meat), oily and white fish (total fish) and egg intakes. No product brand name 136 
or serving size information was available for the dairy intakes, however the average serving 137 
intake size in a representative study of older Irish adults (>65 yrs) recruited at the same time 138 
period (as part of the National Adult Nutrition Study (NANs)) was 114 grams (g) for yogurt, 139 
123g for milk and 35g for cheese [23].   140 
 141 
Biochemical analysis 142 
A non-fasting blood sample (50ml) was collected by venipuncture into an evacuated clotting 143 
tube (Sarstedt; Numbrecht, Germany) by a trained phlebotomist. Samples were kept chilled 144 
and centrifuged (3000 rpm for 15 minutes) within 3 hours of collection and serum aliquots 145 
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were labeled and stored at -80°C until required for analysis. Serum bone bio-markers were 146 
measured in duplicate using an automated enzyme immunoassay method (EIA) following the 147 
manufacturer’s instructions (Triturus®, Immunodiagnostics (IDS) limited, Boldon, Tyne & 148 
Wear, UK). Inter-assay CVs were as follows: Serum osteocalcin (OC) <4.5% (reference range 149 
for males of 9.6-40.8 ng/ml and for postmenopausal women 12.8-55.0 ng/ml), C-terminal 150 
telopeptides of type I collagen (CTX) <3.1% (reference range is 0.020 ng/mL to 3.380 ng/ml), 151 
Bone specific alkaline phosphatase (BAP) <1.5 % (reference range for males of 5.7-32.9 µg/ml 152 
and for postmenopausal women 5.5-27.1 µg/ml) and Tartrate-resistant acid phosphatase 153 
(TRAP 5b) <1.6% (reference range for males of 55-79 ng/ml and for postmenopausal women 154 
41-81 ng/ml). Intact PTH was measured at St. James’s Hospital, Dublin using an 155 
electrochemiluminescence immunoassay (ECLIA) (Modular E170, Roche Diagnostics, 156 
Dublin, Ireland) with an inter-assay CV of <2.9% and an assay measurement range of 1.2 – 157 
5000 pg/ml. Vitamin D (25-hydroxyvitamin D (25(OH)D)) concentrations were quantified 158 
using LC-MS/MS (API 4000; AB SCIEX; Chromsystems GmbH) with an inter-assay CV of 159 
<5.7% (detection range 7.5 – 624 nmol/L)  [19,20]. Renal function tests (creatinine) were 160 
analyzed using a Roche Cobas c701 (Roche 8000 modular system) with an inter-assay CV 161 
<5%. Glomerular filtration rate (GFR) was estimated by use of the Cockcroft-Gault equation. 162 
 163 
BMD and Physical function measures 164 
BMD was measured by dual energy X-ray absorptiometry (DXA) (Lunar iDXA™, UK) 165 
performed at the hip, femoral neck and the vertebral column by a fully trained operator 166 
according to ionizing radiation medical exposure regulations (IRMER) and scans were 167 
subsequently interpreted with the assistance of a radiographer. Results were expressed as grams 168 
of BMD per square centimeter (g/cm2) and as T-scores using the manufacturer’s reference 169 
database. Osteopenia was defined as a BMD T-score between -1.0 and -2.5 at any site and 170 
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osteoporosis defined as a BMD T score > -2.5 at any site (below the young adult mean) [24]. 171 
Physical function was primarily assessed by use of the Timed Up and Go test (TUG) which 172 
measured the time it took a participant to rise from a chair, walk three meters, turn around, 173 
walk back to the chair and sit down again. A score of 12 seconds or more has been reported as 174 
an indication of reduced mobility [25]. Additional functionality measures included the PSM 175 
and the Instrumental Activities of Daily living scale (IADL) [26]. 176 
 177 
Statistical analysis 178 
The statistical analysis was performed using the Statistical Package for Social Sciences 179 
(Version 23.0; SPSS UK Ltd; Chersey, UK). Data were assessed for normality and where 180 
necessary, data were log-transformed for normalization purposes. Data within tables are 181 
primarily expressed as adjusted means with 95% confidence intervals. Estimated marginal 182 
means were adjusted for age, gender, BMI, GFR, calcium and vitamin D supplement usage 183 
(yes/no). Where appropriate, an independent Student’s T-test, one-way ANOVA or ANCOVA 184 
with pair-wise comparisons were applied to determine statistical differences between groups 185 
(P<0.05). Data were corrected for multiple comparison using the Bonferroni correction.  186 
Categorical variables were assessed by chi-square analysis. Hierarchical multiple regression 187 
models with adjustment for age, gender, education, BMI, smoking status, alcohol consumption, 188 
physical activity (in past two weeks), vitamin D and calcium supplement usage, 25(OH)D 189 
concentration, daily milk, yogurt, cheese, total meat (red meat and poultry), total fish (oily and 190 
white) and daily egg servings were applied to determine significant predictors of BMD 191 
concentrations and physical function measure scores. To determine the predictors of bone 192 
health (osteopenia or osteoporosis), a multinomial logistic regression model was used (with 193 
normal bone health as the reference category) with relevant co-predictors including the nominal 194 
variables: age, BMI, education, 25(OH)D concentration, PTH concentration, GFR, frequency 195 
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of daily servings of milk, yogurt, cheese, total meat, total fish and eggs and the categorical 196 
variables: gender (reference male), vitamin D supplement user (reference non-vitamin D 197 
supplement user), non-smoker (reference smoker), non-alcohol consumer (reference alcohol 198 
consumer), physical activity: yes (reference physical activity: no). 199 
 200 
Results 201 
General characteristics of participants in the TUDA cohort as defined by gender are shown in 202 
Table 1. The majority of participants were female (67.4%), who were significantly older 203 
(P=0.004), lighter (P<0.0001), and contained a higher proportion of individuals receiving 204 
vitamin D or calcium supplements (P<0.0001) in comparison with males. A higher percentage 205 
of females were yogurt consumers with mean daily yogurt servings significantly higher than 206 
males (0.42/d vs. 0.32/d respectively) (P<0.0001). In yogurt consumers, the proportion who 207 
answered yes to physical activity was 80.9% while in non-consumers it was 74.7%. In 208 
participants who had measures of BMD performed, 41.3% had osteopenia while 27% had 209 
osteoporosis which was more common in females than males (35.6% vs 14.8% respectively; 210 
P<0.0001).  Data for BMD, the bone biomarker concentrations and physical function measures 211 
across the frequency of daily yogurt intakes (split by gender) are presented in Table 2 and Table 212 
3. In females, after adjustment for covariates (and exclusion of those receiving medications 213 
that may affect BMD), total hip BMD was 3.1% higher (P=0.005) and femoral neck BMD was 214 
3.9% higher (P<0.0001) in the high yogurt consumers (>once per day serving) compared to the 215 
non-consumers (<once per week serving/never). In males, vertebral BMD was 4.1% higher in 216 
low yogurt consumers compared with non-consumers (P=0.028). Similarly, mean vitamin D 217 
concentrations (after exclusion of those receiving vitamin D supplements) were 12.9% higher 218 
(P=0.006) and mean TRAP 5b concentrations were 9.5% lower (P=0.003) in the male high 219 
yogurt consumers compared to the non-consumers. No significant change in concentration 220 
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across yogurt consumption was observed for PTH or the remaining bone biomarkers in either 221 
gender.  222 
 223 
For physical function measures in females, non-consumers of yogurt were 0.9 seconds (6.7%) 224 
slower than the high consumers (13.8 vs 12.9 seconds; P=0.020). Similarly, PSM and IADL 225 
scores were significantly higher in the yogurt high consumers compared to the non-consumers 226 
(P=0.010 & P=0.003 respectively). No significant difference was observed for males. This 227 
analysis was then repeated to examine BMD, bone biomarker and physical function measures 228 
across frequency of milk and cheese intakes (Supplemental Tables 2-5). No significant 229 
difference was observed across milk intake frequencies for BMD or bone biomarker 230 
concentrations. However, TUG scores were significantly lower in the non-milk consumers 231 
compared to the high milk consumers in both men and women (P<0.05). In addition there were 232 
slight increases in PSM and IADL scores across milk intakes in both genders while no 233 
significant difference was observed across cheese intake frequencies for any of the measures.  234 
 235 
In a hierarchical multiple regression model (Table 3) examining predictors of BMD, bone 236 
markers and physical function measures, increasing yogurt intake was a significant positive 237 
predictor for BMD in females at all three sites after adjustment for relevant covariates. For 238 
instance, with each unit increase in yogurt intake (i.e., an increase of one serving per week) 239 
total hip BMD increased by 0.015 g/cm2 (P=0.002), vertebral BMD by 0.026 g/cm2 (P=0.005) 240 
and femoral neck BMD increased by 0.023 g/cm2 (P<0.0001). Furthermore, with each yogurt 241 
unit increase, TUG scores decreased by 0.59 seconds (P=0.021).  In men only, with each unit 242 
increase in yogurt intake, concentrations of TRAP 5b decreased by 0.118 µg/L (P<0.0001). 243 
Significant predictors of bone health status are outlined in Table 4. Daily yogurt intake was a 244 
significant predictor of bone health with each unit increase in yogurt intake associated with a 245 
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31% lower risk of having osteopenia (OR 0.69; 95% CI 0.49 – 0.96; P=0.032) and a 39% lower 246 
risk of being characterized as osteoporotic (OR 0.61; 95% CI 0.42 - 0.89; P=0.012) in females 247 
and in males a 52% lower risk of osteoporosis (OR 0.48; 95% CI 0.24 - 0.96; P=0.038). For 248 
females, those on vitamin D supplements had a significantly reduced risk of osteopenia (OR 249 
0.51; 95% CI 0.34 – 0.76; P=0.001) and a significantly reduced risk of osteoporosis (OR 0.41; 250 
95% CI 0.26 – 0.64; P<0.0001). For males, those on vitamin D supplements also had a 251 
significantly reduced risk of osteoporosis (OR 0.40; 95% CI 0.22 – 0.72; P=0.003). 252 
 253 
Discussion  254 
In this study we observed significant positive associations of increased frequency of yogurt 255 
intakes with bone health and measures of physical function in a cohort of older adults. Females 256 
with the highest yogurt intakes had significantly higher BMD and better physical function 257 
scores compared to individuals with the lowest intakes. Furthermore, we show for the first time 258 
that, after adjustment for covariate predictors, each unit increase in yogurt intake significantly 259 
decreased the odds of being characterized as osteopenic or osteoporotic in women and as 260 
osteoporotic in men. 261 
 262 
The significant positive associations of yogurt with BMD within this large study are consistent 263 
with previous observations from the Framingham Offspring observational study [17] In 2,733 264 
adults (26-85 yrs), higher yogurt intake was positively associated with trochanteric BMD over 265 
a 12-year follow-up with a weak protective trend of yogurt (but not other dairies) on the risk 266 
of hip fracture. In a cohort of 61,000 Swedish women (aged 39-74 yrs), fermented milk 267 
products (yogurt) were associated with a significant decrease in fracture incidence and 268 
mortality over a mean follow-up of 20 years. With each increase in fermented dairy intakes, 269 
hip fractures were reduced by 10-15% [18]. Although the current data-set did not have data on 270 
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fracture incidence, the effect of increased yogurt intake seen in this cohort has the potential to 271 
reduce non-vertebral fractures by up to 46% in women, as fracture risk reduction has been 272 
modelled as 46% decrease for 3% hip BMD increase [27]. However it is important to note that 273 
the meta-analysis [27] was conducted in women all diagnosed with osteoporosis whereas in 274 
the current study only 60% of the women were osteoporotic and thus the potential for yogurt 275 
to reduce fractures at the same rate should be viewed with caution. The potential protective 276 
effects of yogurt on bone health are also supported by the positive associations of yogurt with 277 
the bone biomarker Trap 5b, the concentrations of which were 9.5% lower in those with the 278 
highest yogurt intake compared to the lowest, though only in men. Trap 5b is a direct marker 279 
of osteoclast number and bone resorption (indicating positive bone balance), with better 280 
sensitivity than CTX (a by-product of collagen breakdown) [28] and has been described as one 281 
of the most sensitive markers to monitor the response of diet intervention on bone resorption 282 
[29]. Significantly fewer men than women were high yogurt consumers, and it is possible this 283 
marker was detecting subtle bone turnover changes in men only as not enough yogurt was being 284 
consumed to affect BMD but enough to affect bone turnover, though this hypothesis needs to 285 
be tested. If the results from the current study are confirmed, there is the potential that increased 286 
yogurt intakes may add an inexpensive and relatively low-risk strategy to improve bone health 287 
in conjunction with bone treatment. However, future research and randomized controlled trials 288 
are needed to explore this approach.  289 
 290 
Notably, this study also observed that greater consumption of yogurt was associated with a 291 
significantly lower TUG score (6.7% difference lowest vs highest yogurt intakes) in women 292 
only. TUG has been described as a composite measure of functional mobility with worse scores 293 
associated with poorer muscle strength and balance, both of which are risk factors for falling 294 
in older adults [30]. Our results are in agreement with Lana et al. who observed that higher 295 
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consumption of yogurt (and milk) was associated with a lower risk of frailty and a lower risk 296 
of a slow walking speed in 1,871 community dwelling older adults [31]. Furthermore, in a 297 
cross-sectional study of elderly Australian women (n 1,456), higher dairy intake was associated 298 
with increased grip strength and decreased likelihood of a lower TUG score [32]. 299 
 300 
A number of potential mechanisms may explain the observed positive associations. Yogurt 301 
naturally contains significant concentrations of bone promoting minerals and vitamins [10-14] 302 
which have also been associated with improved frailty measures [33,34]. In data from the 303 
Framingham Heart Study offspring cohort, yogurt consumers were 47% and 55% less likely to 304 
have inadequate intakes of vitamins B2 and B12 (respectively) [35], while in 2,797 Italian 305 
adults (aged 18-97 yrs), yogurt consumers were more likely to have adequate intakes of 306 
vitamins and minerals compared to non-consumers [36]. Yogurt also contains significant 307 
quantities of protein, bio-active peptides and bio-cultures which have been associated with 308 
bone health and immunological benefits [37-43]. For example, yogurt (and other dairy 309 
products) contain branched chain amino acids (BCAAs) which are potent stimulators of muscle 310 
protein synthesis [44,45]. Furthermore, in a recent review it was suggested that the modifiable 311 
nature of the gut microbiome could provide a potential therapeutic target to intervene in 312 
musculoskeletal conditions of aging [46]. It is perhaps this unique combination of macro and 313 
micronutrients with bio-active compounds within yogurt that confers bone promotion and 314 
improved physical function. It is also possible that increased yogurt intakes could also be a 315 
reflection of a long term dietary habit of an overall healthy eating pattern and lifestyle [36], 316 
though diet quality (including vitamin D and calcium) was adjusted for in the current analysis. 317 
Yogurt has been the target of some criticism, especially with the renewed concerns regarding 318 
excess sugar intakes and associations with obesity [47] given that some processed ‘sweetened’ 319 
yogurts can contain substantial quantities of sugar [48]. Yet not all yogurts have a high sugar 320 
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content [49] and further exploration is required to identify the types of yogurts and the 321 
individual components within that may exhibit health benefits.     322 
  323 
We also examined the associations of the other dairy products (milk and cheese) with BMD 324 
and functionality. We observed no significant difference in BMD across milk intakes, in line 325 
with inconsistent data from previous observational studies. For example, some studies have 326 
observed strong associations between childhood and adolescent milk consumption with BMD 327 
[50]. For older adults (>60 yrs), studies have observed no associations or a negative association 328 
of milk intakes with fracture risk [50]. The majority of positive randomized trials with milk 329 
which have observed significant decreases in the concentrations of bone biomarkers and 330 
improvements in bone metabolism have all utilized fortified milk [51]. The milk intakes in the 331 
current study were not heavily fortified at this time period (2008-2012) and could account for 332 
the lack of any such association. Furthermore, we have previously reported that in this 333 
population, with increasing age, milk intakes increased while yogurt intakes significantly 334 
decreased [22]. This could help explain why some of the physical function measures became 335 
poorer with increased milk intakes. As milk intakes increased, we suggest that there was a loss 336 
of a particular protective component within the yogurt that enhanced bone health/improved 337 
physical function, though this hypothesis requires verification. Interestingly, we observed no 338 
significant associations of cheese intakes with BMD though male participants with 339 
osteoporosis were more likely to have a higher frequency of cheese consumption. Cheese 340 
products generally have a different nutritional profile in comparison with yogurts and we 341 
previously observed in TUDA that cheese intakes had no significant effect on the 342 
concentrations of vitamin D, folate, vitamin’s B12, B6 or B2 [22]. Furthermore, it has been 343 
suggested that the high sodium content of certain cheeses could be less beneficial for bone 344 
health by negatively altering calcium metabolism, though few studies have examined this issue 345 
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[52] and the sodium-induced calciuria hypothesis has not been supported by any long term 346 
observations. Moreover, fortified cheese products have been positively associated with bone 347 
metabolism [53]. Further research is needed to identify the relationship between cheese intakes 348 
and BMD in men.  349 
 350 
Our study has several limitations. The data are observational and cross-sectional, and such 351 
observed associations between yogurt intakes and bone health do not necessarily indicate a 352 
causal relationship. However, one of the major strengths of this study was the size, as to the 353 
best of our knowledge it is the largest observational study conducted to date investigating such 354 
associations. Potential weaknesses of this study also include our reliance on self-reported 355 
intakes and we were unable to quantify the dairy or yogurt intakes through food dairies or other 356 
more quantitative dietary collection (and thus did not have information on serving sizes or 357 
product types). However, although we could not adjust for total energy intake, we did adjust 358 
for frequency of intake of other important dietary components including meat, fish, egg and 359 
other dairy constituents which can give a proxy measure of diet quality. Furthermore, those 360 
with severe cognitive impairment or frailty were removed from the analysis to increase recall 361 
accuracy. 362 
 363 
In conclusion, to our knowledge, this is the largest study to demonstrate an association between 364 
the frequency of yogurt intakes, BMD, bone biomarkers and measures of physical function 365 
exclusively within free-living, older adults (>60y). The findings provide evidence that lower 366 
frequency of yogurt intake is significantly associated with a lower BMD and that improving 367 
yogurt intakes could be a valuable and cost-effective health measure for maintaining bone 368 
health and in reducing frailty in older adults. Future RCT trials are required to assess and 369 
investigate the efficacy of such approaches.  370 
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Table 1. Demographic and health characteristics of the TUDA cohort study by gendera 
Variable 
Total                       
(n= 4,310) 
Male                  
(n= 1,405) 
Female               
(n= 2,905) 
 
P value 
Age,b y 73.1 (7.9) 72.6 (7.8) 73.3 (8.0) 0.004 
60-69,c y n (%) 1690 (39.2) 567 (40.4) 1123 (38.7) 0.284 
70-79,c y n (%) 1697 (39.4) 568 (40.4) 1129 (38.9) 0.325 
 >80,c n (%) 923 (21.4) 270 (19.2) 653 (22.5) 0.014 
Age Finished Education,b (yrs)      16.2 (3.0) 16.2 (3.2) 16.2 (2.9) 0.564 
Health & Lifestyle     
 BMI,b kg/m2 28.0 (5.3) 28.6 (4.4) 27.7 (5.7) <0.0001 
 GFR,b ml/min 69.4 (24.4) 77.1 (25.4) 65.6 (22.9) <0.0001 
 Current smoker,c n (%) 515 (12.0) 156 (11.1) 359 (12.4) 0.231 
 Current alcohol consumer,c n (%) 2551 (59.2) 919 (65.5) 1632 (56.2) <0.0001 
 Physical activity in last two weeks,c n (%) 3403 (79.0) 1094 (77.9) 2309 (79.5) 0.214 
 Receives Bone medications,c n (%) 1484 (34.4) 244 (17.4) 1240 (42.7) <0.0001 
 Yogurt consumer,c n (%) 2658 (61.7) 725 (51.6) 1933 (66.5) <0.0001 
 Milk (as a drink) consumer,c n (%) 1806 (42.9) 640 (46.4) 1166 (41.1) 0.001 
 Cheese consumer,c n (%) 3651 (84.7) 1209 (86.0) 2442 (84.1) 0.089 
Supplement use,c n (%)     
 Vitamin D supplement user 2042 (47.8) 447 (33.2) 1595 (58.4) <0.0001 
 Calcium supplement user 1742 (40.4) 308 (21.9) 434 (49.4) <0.0001 
 Phosphate supplement user 262 (6.1) 82 (5.8) 180 (6.2) 0.643 
a Values are means (±SD) for continuous variables.                                                                                                                                                                            
b Student’s independent t test was used to test differences between log-transformed continuous variables.                                                                                         
c Chi-square tests were used to test differences between categorical variables.                                                                                              
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Table 2. Comparison of bone mineral density (BMD), biomarkers of bone health and mean frailty measures across frequencies of daily yogurt intake in 
females in the TUDA cohort studya 
  Tertile of daily yogurt intakes 
               Non-consumer Low consumer High consumer 
 
       Mean yogurt frequency 
  (0.0 daily / <once per week/never) 
Mean yogurt frequency 
(0.34 daily / 2-3 times per week) 
Mean yogurt frequency 
(1.03 daily / >once per day) 
                    n=  970 n=  826 n= 1109 
Variable n Mean 95% CI n Mean 95% CI n Mean 95% CI 
BMD region,b g/cm2          
 Total Hip 320 0.890 0.877 – 0.903  331 0.904 0.891 – 0.917 406 0.918* 0.907 – 0.930 
 Femoral Neck 319 0.824 0.812 – 0.836 331 0.843 0.831 – 0.855 405 0.857** 0.846 – 0.867 
 Vertebral 260 1.005 0.984 – 1.025 251 1.027 1.006 – 1.047 330 1.036 1.018 – 1.054 
Bone health biomarkers          
 CTX,b ng/ml 226 0.34 0.32 – 0.36 258 0.33 0.31 – 0.35 278 0.32 0.30 – 0.34 
 OC,b ng/ml 225 19.2 18.0 – 20.5 252 18.7 17.5 – 19.8 278 18.8 17.7 – 19.9 
 BAP,b µg/L 226 17.8 16.9 – 18.7 252 18.0 17.1 – 18.8 278 17.7 16.9 – 18.5 
 TRAP 5b,b µg/L  226 3.30 3.17 – 3.43 252 3.29 3.17 – 3.41 279 3.24 3.12 – 3.35 
 25(OH)D,c nmol/L 412 41.0 38.9 – 43.2 347 43.4 41.1 – 45.7 361 43.5 41.2 – 45.8 
 PTH,b pg/ml 505 50.0 47.5 – 52.5 446 47.0  44.4 – 49.7 578 46.3 43.9 – 48.6 
Physical function measuresc          
 Timed up and Go, (sec) 868 13.8 13.3 – 14.2 740 13.0 12.5 – 13.5 1,016 12.9* 12.5 – 13.3 
 IADL 906 24.4 24.2 – 24.6 751 24.5 24.3 – 24.8 1,014 24.8* 24.6 – 25.0 
 PSM 913 22.9 22.8 – 23.0 767 22.9 22.8 – 23.0 1,035 23.1* 23.0 – 23.2 
 a Values are estimated marginal means (95% CI) adjusted for multiple covariates. Differences in means were assessed by pair-wise comparisons and adjusted for multiple 
comparisons: Bonferroni correction. *,**Different from the lowest yogurt intake tertile: *P<0.05, **P<0.0001. Non-consumer frequency range (0 – 0.07 units / <once per 
week/never); low consumer frequency range (>0.07- 0.50 units / >once per week to 3-4 times per week); high consumer frequency range (>0.50 – 2.00 units / >3-4 times per 
week to twice per day). 
bAdjusted for age, education, BMI, GFR, physical activity, total daily serving milk (glass only), total daily serving of cheese, calcium or vitamin D supplements (Participants 
receiving medications that could affect bone metabolism were removed from the analysis).                                                       
cAdjusted for age, BMI, total daily serving milk (glass only), total daily serving of cheese; (participants receiving vitamin D supplements were removed from the 25(OH)D 
analysis). Abbreviations: BAP, Bone specific alkaline phosphatase; CTX, C-terminal telopeptides of type I collagen; IADL, Instrumental Activities of Daily Living Scale; OC, 
Osteocalcin; PSM, Physical Self-Maintenance Scale; PTH, Parathyroid hormone; TRAP 5b, Tartrate-resistant acid phosphatase 5b; /d, per day; 25(OH)D, 25-hydroxyvitamin 
D. OC reference range for males of 9.6-40.8 ng/ml and for postmenopausal women 12.8-55.0 ng/ml; CTX reference range is 0.020 ng/mL to 3.380 ng/ml; BAP reference range 
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for males of 5.7-32.9 µg/ml and for postmenopausal women 5.5-27.1 µg/ml; TRAP 5b reference range for males of 55-79 ng/ml and for postmenopausal women 41-81 ng/ml; 
Intact PTH measurement range of 1.2 – 5000 pg/ml. and 25(OH)D detection range 7.5-624 nmol/L. 
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Table 3. Comparison of bone mineral density (BMD), biomarkers of bone health and mean frailty measures across frequencies of daily yogurt intake in males 
in the TUDA cohort studya 
  Tertile of daily yogurt intakes 
               Non-consumer Low consumer High consumer 
 
       Mean yogurt frequency 
  (0.0 daily / <once per week/never) 
Mean yogurt frequency 
(0.29 daily / 2-3 times per week) 
Mean yogurt frequency 
(1.00 daily / >once per day) 
                    n=  680 n=  392 n= 333 
Variable n Mean 95% CI n Mean 95% CI n Mean 95% CI 
BMD region,b g/cm2          
 Total Hip 339 1.041 1.026 – 1.056  239 1.057 1.039 – 1.075 185 1.058 1.038 – 1.079 
 Femoral Neck 339 0.925 0.911 – 0.939 239 0.945 0.928 – 0.962 185 0.947 0.928 – 0.966 
 Vertebral 271 1.207 1.183 – 1.231 180 1.258* 1.229 – 1.287 134 1.235 1.201 – 1.269 
Bone health biomarkers          
 CTX,b ng/ml 306 0.27 0.25 – 0.29 231 0.27 0.25 – 0.29 169 0.27 0.25 – 0.29 
 OC,b ng/ml 305 14.7 13.9 – 15.7 231 14.9 13.9 – 15.8 169 15.0 13.8 – 16.2 
 BAP,b µg/L 305 16.2 15.3 – 17.1 231 15.7 14.6 – 16.7 168 16.2 15.0 – 17.5 
 TRAP 5b,b µg/L  306 2.96 2.87 – 3.06 231 2.89 2.78 – 3.00 169 2.69** 2.56 – 2.82 
 25(OH)D,c nmol/L 443 41.8 39.7 – 44.0 243 49.3** 46.3 – 52.2 205 47.6* 44.4 – 50.8 
 PTH,b pg/ml 527 45.2 42.7 – 47.8 310 43.7  40.4 – 47.0 258 47.9 44.3 – 51.5 
Physical function measuresc          
 Timed up and Go, (sec) 627 13.3 12.6 – 13.9 361 12.0* 11.1 – 12.8 302 12.7 11.8 – 13.6 
 IADL 636 24.6 24.3 – 24.9 372 25.4* 25.0 – 25.8 309 24.7 24.4 – 25.2 
 PSM 647 23.2 23.1 – 23.4 374 23.4 23.2 – 23.5 315 23.2 23.0 – 23.4 
a Values are estimated marginal means (95% CI) adjusted for multiple covariates. Differences in means were assessed by pair-wise comparisons and adjusted for multiple 
comparisons: Bonferroni correction. *,**Different from the lowest yogurt intake tertile: *P<0.05, **P<0.0001. Non-consumer frequency range (0 – 0.07 units / <once per 
week/never); low consumer frequency range (>0.07- 0.50 units / >once per week to 3-4 times per week); high consumer frequency range (>0.50 – 2.00 units / >3-4 times per 
week to twice per day). 
bAdjusted for age, education, BMI, GFR, physical activity, total daily serving milk (glass only), total daily serving of cheese, calcium or vitamin D supplements (Participants 
receiving medications that could affect bone metabolism were removed from the analysis).                                                       
cAdjusted for age, BMI, total daily serving milk (glass only), total daily serving of cheese; (participants receiving vitamin D supplements were removed from the 25(OH)D 
analysis). Abbreviations: BAP, Bone specific alkaline phosphatase; CTX, C-terminal telopeptides of type I collagen; IADL, Instrumental Activities of Daily Living Scale; OC, 
Osteocalcin; PSM, Physical Self-Maintenance Scale; PTH, Parathyroid hormone; TRAP 5b, Tartrate-resistant acid phosphatase 5b; /d, per day; 25(OH)D, 25-hydroxyvitamin 
D. OC reference range for males of 9.6-40.8 ng/ml and for postmenopausal women 12.8-55.0 ng/ml; CTX reference range is 0.020 ng/mL to 3.380 ng/ml; BAP reference range 
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for males of 5.7-32.9 µg/ml and for postmenopausal women 5.5-27.1 µg/ml; TRAP 5b reference range for males of 55-79 ng/ml and for postmenopausal women 41-81 ng/ml; 
Intact PTH measurement range of 1.2 – 5000 pg/ml. and 25(OH)D detection range 7.5-624 nmol/L. 
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Table 4. Yogurt consumption as a predictor of markers of bone health and physical function in the TUDA cohort studya 
  
Total Hip          
BMD,b  
Femoral Neck 
BMD,b  
Vertebral  
BMD,b  
TRAP 5b,b 
Timed up and 
go,c  IADLc PSMc 
  g/cm2  g/cm2 g/cm2  µg/L sec  
Variable  β  β  β  β  β  β  β 
Total sample 0.015 (0.007) 0.023 (0.006) 0.026 (0.011) -0.118 (0.055) -0.599 (0.252) 0.220 (0.115) 0.084 (0.054) 
P-value 0.015 <0.0001 0.016 0.032 0.018 0.056 0.121 
        
Female only 0.024 (-0.008) 0.031 (0.007) 0.034 (0.012) 0.015 (-0.077) -0.641 (0.277) 0.272 (0.126) 0.157 (0.065) 
P-value 0.002 <0.0001 0.005 0.847 0.021 0.031 0.016 
        
Male only 0.004 (-0.013) 0.009 (-0.012) 0.012 (-0.021) -0.292 (0.080) -0.496 (-0.543) 0.06 (-0.248) -0.141 (-0.096) 
P-value 0.761 0.431 0.557 <0.0001 0.361 0.809 0.144 
 aValues are unstandardized Beta (β) coefficients (standard error) derived from a hierarchical multiple regression analysis.  
bAdjustment for age, gender (total sample only), education, BMI, smoking status, alcohol consumption, vitamin D or calcium supplement use, 25(OH)D, 
GFR, physical activity, total daily serving milk (glass only), total daily serving of cheese, total daily serving of meat (red meat and poultry), total daily serving 
of fish (white and oily) and total daily serving of eggs. (Participants receiving medications that could affect bone metabolism were removed from the 
analysis).  
cAdjustment for age, gender (total sample only), BMI, total daily serving milk (glass only), total daily serving of cheese, total daily serving of meat (red meat 
and poultry), total daily serving of fish (white and oily) and total daily serving of eggs.   
Abbreviations: IADL, Instrumental Activities of Daily Living Scale; PSM, Physical Self-Maintenance Scale; TRAP 5b, Tartrate-resistant acid phosphatase 
5b; 25(OH)D, 25-hydroxyvitamin D. 
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Table 5. The predictors of bone health status of females within the TUDA cohort studya 
  
Odds ratio [95% CI] 
  
Odds ratio [95% CI] 
  
Variable P Value P Value 
  Osteopenia vs Normal    Osteoporosis vs Normal      
 (n = 411 vs 266)  (n = 360 vs 266)  
Age (y) 1.02 [0.99-1.06] 0.073 1.04 [1.00-1.08] 0.018 
BMI (kg/m2) 0.93 [0.89-0.96] <0.0001 0.79 [0.76-0.83] <0.0001 
25(OH)D (nmol/L) 0.99 [0.99-1.00] 0.869 1.00 [0.99-1.01] 0.148 
Vitamin D supplement user 0.51 [0.34-0.76] 0.001 0.41 [0.26-0.64] <0.0001 
PTH (pg/mL) 1.00 [0.99-1.01] 0.322 1.00 [0.99-1.01] 0.068 
Education (yrs) 0.97 [0.91-1.03] 0.360 0.95 [0.88-1.02] 0.181 
Non-Smokerb 0.89 [0.50-1.58] 0.710 0.61 [0.34-1.12] 0.116 
Non-Alcohol userc 0.85 [0.60-1.20] 0.372 1.06 [0.72-1.57] 0.740 
Physical activity: Yesd 0.89 [0.56-1.43] 0.645 0.61 [0.35-1.56] 0.078 
GFR (ml/min) 0.99 [0.98-1.00] 0.810 1.00 [0.99-1.01] 0.601 
Daily yogurt serving 0.69 [0.49-0.96] 0.032 0.61 [0.42-0.89] 0.012 
Daily milk serving 0.77 [0.53-1.11] 0.167 0.75 [0.49-1.13] 0.175 
Daily cheese serving 1.05 [0.65-1.69] 0.831 1.18 [0.70-2.00] 0.516 
Daily meat serving 0.91 [0.58-1.41] 0.676 1.16 [0.70-1.92] 0.546 
Daily fish serving 0.94 [0.39-2.26] 0.892 0.48 [0.17-1.35] 0.168 
Daily egg serving 1.24 [0.63-2.46] 0.528 1.66 [0.76-3.61] 0.201 
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aValues are odds ratios (95 % CI lower and upper) derived from a multi-nominal logistic regression analysis. Overall reference category is normal bone health 
based on the WHO definition of osteopenia and osteoporosis [24] using the combination of total hip, femoral neck or vertebral BMD where available. 
Participants receiving medications that could affect bone metabolism were removed from the analysis. 
bReference is smoker  
cReference is user. 
dReference is physical activity: No in the last two weeks
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Table 6. The predictors of bone health status of males within the TUDA cohort study1 
  
Odds ratio [95% CI] 
  
Odds ratio [95% CI] 
  
Variable P Value P Value 
  Osteopenia vs Normal    Osteoporosis vs Normal      
 (n = 332 vs 315)  (n = 104 vs 315)  
Age (y) 0.98 [0.95-1.01] 0.318 1.01 [0.96-1.06] 0.643 
BMI (kg/m2) 0.96 [0.91-1.01] 0.128 0.80 [0.73-0.87] <0.0001 
25(OH)D (nmol/L) 1.00 [0.99-1.00] 0.703 0.99 [0.98-1.00] 0.213 
Vitamin D supplement user 0.79 [0.52-1.21] 0.286 0.40 [0.22-0.72] 0.003 
PTH (pg/mL) 1.00 [0.99-1.01] 0.238 1.01 [1.00-1.01] 0.026 
Education (yrs) 0.95 [0.91-1.00] 0.106 0.96 [0.88-1.04] 0.389 
Non-Smoker3 0.58 [0.32-1.07] 0.085 0.39 [0.18-0.85] 0.019 
Non-Alcohol user2 0.77 [0.53-1.11] 0.170 0.94 [0.54-1.64] 0.846 
Physical activity: Yes4 0.59 [0.37-0.92] 0.022 1.09 [0.51-2.35] 0.812 
GFR (ml/min) 0.98 [0.97-0.99] 0.016 0.98 [0.97-1.00] 0.128 
Daily yogurt serving 0.88 [0.59-1.30] 0.537 0.48 [0.24-0.96] 0.038 
Daily milk serving 0.84 [0.58-1.19] 0.338 1.58 [0.99-2.52] 0.055 
Daily cheese serving 1.79 [1.11-2.88] 0.016 2.36 [1.16-4.82] 0.018 
Daily meat serving 0.64 [0.42-0.99] 0.045 1.10 [0.58-2.07] 0.756 
Daily fish serving 0.74 [0.30-1.81] 0.522 0.69 [0.17-2.85] 0.617 
Daily egg serving 1.27 [0.69-2.32] 0.439 1.16 [0.47-2.86] 0.740 
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1Values are odds ratios (95 % CI lower and upper) derived from a multi-nominal logistic regression analysis. Overall reference category is normal bone health 
based on the WHO definition of osteopenia and osteoporosis [24] using the combination of total hip, femoral neck or vertebral BMD where available. 
Participants receiving medications that could affect bone metabolism were removed from the analysis. 
2Reference is user.  
3Reference is smoker. 
4Reference is physical activity: No in the last two weeks
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Supplemental Figure 1. Study Design for yogurt intake frequency analysis within the TUDA cohort 
study 
Abbreviations: BAP, Bone specific alkaline phosphatase; CTX, C-terminal telopeptides of type I 
collagen; OC, Osteocalcin; Parathyroid hormone; TRAP 5b, Tartrate-resistant acid phosphatase 5b; 
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 Supplemental Table 1. Calculation of daily yogurt and dairy intakes in the TUDA cohort study1 
Questionnaire  Dairy Intake  
Frequency 
Daily Yogurt intake 
frequency 
Daily Milk intake 
frequency 
Daily Cheese intake  
frequency 
Twice per day 2 2 2 
Once per day 1 1 1 
5-6 times per week 0.785 0.785 0.785 
3-4 times per week 0.5 0.5 0.5 
1-2 times per week 0.21 0.21 0.21 
<Once per week 0.07 0.07 0.07 
1Values are self-reported intakes derived from a modified food frequency questionnaire (FFQ)  
 
 
 
 
 
 
 
 
 
 
Supplemental Table 2. Comparison of bone mineral density (BMD), biomarkers of bone health and mean frailty measures across frequencies of daily milk 
intake in females in the TUDA cohort studya 
  Tertile of daily milk intakes 
               Non-consumer Low consumer High consumer 
 
       Mean milk frequency 
  (0.0 daily / <once per week/never) 
Mean milk frequency 
(0.18 daily / 1-2 times per week) 
Mean milk frequency 
(1.00 daily / >once per day) 
                    n= 1,746  n= 305  n= 854  
Variable n Mean 95% CI n Mean 95% CI n Mean 95% CI 
BMD region,b g/cm2          
 Total Hip 673 0.907 0.898 – 0.916  133 0.903 0.883 – 0.923 252 0.902 0.888 – 0.917 
 Femoral Neck 672 0.845 0.837 – 0.853 133 0.838 0.820 – 0.857 250 0.838 0.824 – 0.852 
 Vertebral 545 1.029 1.015 – 1.043 99 1.026 0.993 – 1.059 197 1.008 0.985 – 1.032 
Bone health biomarkers          
 CTX,b ng/ml 465 0.33 0.32 – 0.35 107 0.34 0.31 – 0.37 184 0.3` 0.29 – 0.34 
 OC,b ng/ml 464 19.2 18.3 – 20.0 107 18.5 16.7 – 20.2 184 18.4 17.1 – 19.8 
 BAP,b µg/L 466 17.8 17.1 – 18.4 107 17.3 16.0 – 18.6 183 18.3 17.3 – 19.3 
 TRAP 5b,b µg/L  566 3.31 3.22 – 3.40 107 3.22 3.04 – 3.41 184 3.21 3.07 – 3.35 
 25(OH)D,c nmol/L 691 43.2 41.5 – 44.8 129 41.8 38.0 – 45.7 301 41.5 39.0 – 44.0 
 PTH,b pg/ml 942 46.7 44.9 – 48.6 167 49.0  44.6 – 53.3 420 49.4 46.7 – 52.1 
Physical function measuresc          
 Timed up and Go, (sec) 1,688 12.8 12.5 – 13.1 295 12.5 11.8 – 13.3 808 13.7* 13.2 – 14.2 
 IADL 1,706 24.9 24.7 – 25.0 298 24.8 24.5 – 25.2 831 24.2* 24.0 – 24.4 
 PSM 1,738 23.1 23.0 – 23.2 302 22.9 22.8 – 23.1 847 22.9* 22.8 – 23.0 
aValues are estimated marginal means (95% CI) adjusted for multiple covariates. Differences in means were assessed by pair-wise comparisons and adjusted for multiple 
comparisons: Bonferroni correction. *,**Different from the lowest milk intake tertile: *P<0.05, **P<0.0001. Non-consumer frequency range (0 – 0.07 units / <once per 
week/never); low consumer frequency range (>0.07- 0.50 units / >once per week to 1-2 times per week); high consumer frequency range (0.50 – 2.00 units / >3-4 times per 
week to twice per day). 
bAdjusted for age, education, BMI, GFR, physical activity, total daily serving of yogurt, total daily serving of cheese, calcium or vitamin D supplements (Participants receiving 
medications that could affect bone metabolism were removed from the analysis).                                                       
cAdjusted for age, BMI, total daily serving yogurt, total daily serving of cheese; (participants receiving vitamin D supplements were removed from the 25(OH)D analysis). 
Abbreviations: BAP, Bone specific alkaline phosphatase; CTX, C-terminal telopeptides of type I collagen; IADL, Instrumental Activities of Daily Living Scale; OC, 
Osteocalcin; PSM, Physical Self-Maintenance Scale; PTH, Parathyroid hormone; TRAP 5b, Tartrate-resistant acid phosphatase 5b; /d, per day; 25(OH)D, 25-hydroxyvitamin 
D. OC reference range for males of 9.6-40.8 ng/ml and for postmenopausal women 12.8-55.0 ng/ml; CTX reference range is 0.020 ng/mL to 3.380 ng/ml; BAP reference range 
for males of 5.7-32.9 µg/ml and for postmenopausal women 5.5-27.1 µg/ml; TRAP 5b reference range for males of 55-79 ng/ml and for postmenopausal women 41-81 ng/ml; 
Intact PTH measurement range of 1.2 – 5000 pg/ml. and 25(OH)D detection range 7.5-624 nmol/L. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                         
Supplemental Table 3. Comparison of bone mineral density (BMD), biomarkers of bone health and mean frailty measures across frequencies of daily cheese 
intake in females in the TUDA cohort studya 
  Tertile of daily cheese intakes 
               Non-consumer Low consumer High consumer 
 
       Mean cheese frequency 
  (0.0 daily / <once per week/never) 
Mean cheese frequency 
(0.33 daily / 2-3 times per week) 
Mean cheese frequency 
(0.95 daily / >once per day) 
                    n=  602 n=  1,673 n= 631 
Variable n Mean 95% CI n Mean 95% CI n Mean 95% CI 
BMD region,b g/cm2          
 Total Hip 241 0.903 0.888 – 0.918  614 0.908 0.899 – 0.918 202 0.898 0.882 – 0.914 
 Femoral Neck 241 0.840 0.826 – 0.854 612 0.846 0.838 – 0.855 202 0.833 0.818 – 0.849 
 Vertebral 187 1.015 0.991 – 1.039 489 1.026 1.011 – 1.041 165 1.026 1.001 – 1.052 
Bone health biomarkers          
 CTX,b ng/ml 192 0.32 0.30 – 0.34 434 0.33 0.31 – 0.35 130 0.34 0.31 – 0.37 
 OC,b ng/ml 192 19.0 17.7 – 20.4 438 18.7 17.8 – 19.6 130 19.4 17.8 – 21.0 
 BAP,b µg/L 192 17.9 16.9 – 18.8 434 18.0 17.3 – 18.6 130 17.2 16.0 – 18.4 
 TRAP 5b,b µg/L  192 3.25 3.11 – 3.39 435 3.28 3.19 – 3.37 130 3.29 3.13 – 3.46 
 25(OH)D,c nmol/L 221 40.6 37.7 – 43.5 532 43.4 41.5 – 45.3 163 39.9 36.5 – 43.3 
 PTH,b pg/ml 335 47.0 44.0 – 50.1 893 46.9  45.1 – 48.8 301 50.7 47.5 – 54.0 
Physical function measuresc          
 Timed up and Go, (sec) 577 13.3 12.8 – 13.9 1,603 12.9 12.6 – 13.2 611 13.2 12.6 – 13.7 
 IADL 583 24.5 24.3 – 24.7 1,634 24.8 24.6 – 24.9 618 24.6 24.4 – 24.9 
 PSM 596 23.0 22.9 – 23.2 1,662 23.0 23.0 – 23.1 629 23.0 22.9 – 23.1 
1Values are estimated marginal means (95% CI) adjusted for multiple covariates. Differences in means were assessed by pair-wise comparisons and adjusted for multiple 
comparisons: Bonferroni correction. No significant difference observed from the lowest cheese intake tertile to the highest. Non-consumer frequency range (0 – 0.07 units / 
<once per week/never); low consumer frequency range (>0.07- 0.50 units / >once per week to 3-4 times per week); high consumer frequency range (>0.50 – 2.00 units / >3-4 
times per week to twice per day). 
2Adjusted for age, education, BMI, GFR, physical activity, total daily serving milk (glass only), total daily serving of yogurt, calcium or vitamin D supplements (Participants 
receiving medications that could affect bone metabolism were removed from the analysis).                                                       
3Adjusted for age, BMI, total daily serving milk (glass only), total daily serving of cheese; (participants receiving vitamin D supplements were removed from the 25(OH)D 
analysis). Abbreviations: BAP, Bone specific alkaline phosphatase; CTX, C-terminal telopeptides of type I collagen; IADL, Instrumental Activities of Daily Living Scale; OC, 
Osteocalcin; PSM, Physical Self-Maintenance Scale; PTH, Parathyroid hormone; TRAP 5b, Tartrate-resistant acid phosphatase 5b; /d, per day; 25(OH)D, 25-hydroxyvitamin 
D. OC reference range for males of 9.6-40.8 ng/ml and for postmenopausal women 12.8-55.0 ng/ml; CTX reference range is 0.020 ng/mL to 3.380 ng/ml; BAP reference range 
for males of 5.7-32.9 µg/ml and for postmenopausal women 5.5-27.1 µg/ml; TRAP 5b reference range for males of 55-79 ng/ml and for postmenopausal women 41-81 ng/ml; 
Intact PTH measurement range of 1.2 – 5000 pg/ml. and 25(OH)D detection range 7.5-624 nmol/L. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                       
Supplemental Table 4. Comparison of bone mineral density (BMD), biomarkers of bone health and mean frailty measures across frequencies of daily cheese 
intake in males in the TUDA cohort studya 
  Tertile of daily cheese intakes 
               Non-consumer Low consumer High consumer 
 
       Mean cheese frequency 
  (0.0 daily / <once per week/never) 
Mean cheese frequency 
(0.34 daily / 2-3 times per week) 
Mean cheese frequency 
(0.95 daily / >once per day) 
                    n=  269 n=  835 n= 304 
Variable n Mean 95% CI n Mean 95% CI n Mean 95% CI 
BMD region,b g/cm2          
 Total Hip 176 1.064 1.043 – 1.088  447 1.048 1.035 – 1.061 140 1.041 1.048 – 1.064 
 Femoral Neck 176 0.953 0.934 – 0.972 447 0.932 0.920 – 0.944 140 0.929 0.907 – 0.951 
 Vertebral 129 1.246 1.211 – 1.280 342 1.221 1.200 – 1.242 114 1.234 1.197 – 1.271 
Bone health biomarkers          
 CTX,b ng/ml 173 0.27 0.25 – 0.30 413 0.27 0.25 – 0.28 120 0.27 0.24 – 0.30 
 OC,b ng/ml 173 15.1 13.9 – 16.3 413 15.0 14.3 – 15.8 121 13.8 12.4 – 15.2 
 BAP,b µg/L 172 16.4 15.2 – 17.6 412 15.8 15.0 – 16.6 120 16.3 14.8 – 17.7 
 TRAP 5b,b µg/L  173 2.94 2.81 – 3.06 413 2.86 2.78 – 2.95 120 2.81 2.66 – 2.97 
 25(OH)D,c nmol/L 163 45.7 42.0 – 49.3 473 45.1 43.0 – 47.2 172 46.3 42.8 – 49.3 
 PTH,b pg/ml 221 44.0 40.0 – 47.9 647 46.3  44.0 – 48.6 227 44.2 40.4 – 48.1 
Physical function measuresc          
 Timed up and Go, (sec) 255 12.1 11.1 – 13.1 804 12.8 12.2 – 13.3 288 13.2 12.3 – 14.2 
 IADL 261 25.1 24.6 – 25.5 815 25.0 24.7 – 25.2 298 24.8 24.3 – 25.2 
 PSM 265 23.4 23.2 – 23.6 828 23.2 23.1 – 23.3 301 23.3 23.1 – 23.5 
aValues are estimated marginal means (95% CI) adjusted for multiple covariates. Differences in means were assessed by pair-wise comparisons and adjusted for multiple 
comparisons: Bonferroni correction. No significant difference observed from the lowest cheese intake tertile to the highest. Non-consumer frequency range (0 – 0.07 units / 
<once per week/never); low consumer frequency range (>0.07- 0.50 units / >once per week to 3-4 times per week); high consumer frequency range (>0.50 – 2.00 units / >3-4 
times per week to twice per day). 
bAdjusted for age, education, BMI, GFR, physical activity, total daily serving milk (glass only), total daily serving of yogurt, calcium or vitamin D supplements (Participants 
receiving medications that could affect bone metabolism were removed from the analysis).                                                       
cAdjusted for age, BMI, total daily serving milk (glass only), total daily serving of cheese; (participants receiving vitamin D supplements were removed from the 25(OH)D 
analysis). Abbreviations: BAP, Bone specific alkaline phosphatase; CTX, C-terminal telopeptides of type I collagen; IADL, Instrumental Activities of Daily Living Scale; OC, 
Osteocalcin; PSM, Physical Self-Maintenance Scale; PTH, Parathyroid hormone; TRAP 5b, Tartrate-resistant acid phosphatase 5b; /d, per day; 25(OH)D, 25-hydroxyvitamin 
D. OC reference range for males of 9.6-40.8 ng/ml and for postmenopausal women 12.8-55.0 ng/ml; CTX reference range is 0.020 ng/mL to 3.380 ng/ml; BAP reference range 
for males of 5.7-32.9 µg/ml and for postmenopausal women 5.5-27.1 µg/ml; TRAP 5b reference range for males of 55-79 ng/ml and for postmenopausal women 41-81 ng/ml; 
Intact PTH measurement range of 1.2 – 5000 pg/ml. and 25(OH)D detection range 7.5-624 nmol/L. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                       
Supplemental Table 5. Comparison of bone mineral density (BMD), biomarkers of bone health and mean frailty measures across frequencies of daily milk 
intake in males in the TUDA cohort studya 
  Tertile of daily milk intakes 
               Non-consumer Low consumer High consumer 
 
       Mean milk frequency 
  (0.0 daily / <once per week/never) 
Mean milk frequency 
(0.18 daily / 2-3 times per week) 
Mean milk frequency 
(0.99 daily / >once per day) 
                    n= 768 n= 201  n= 438 
Variable n Mean 95% CI n Mean 95% CI n Mean 95% CI 
BMD region,b g/cm2          
 Total Hip 424 1.050 1.036 – 1.063  132 1.050 1.026 – 1.074 207 1.051 1.032 – 1.071 
 Femoral Neck 424 0.939 0.926 – 0.951 132 0.936 0.914 – 0.958 207 0.932 0.915 – 0.950 
 Vertebral 331 1.234 1.213 – 1.256 98 1.216 1.176 – 1.256 156 1.226 1.195 – 1.257 
Bone health biomarkers          
 CTX,b ng/ml 392 0.26 0.25 – 0.28 125 0.27 0.25 – 0.30 189 0.28 0.26 – 0.30 
 OC,b ng/ml 391 15.0 14.3 – 15.8 125 14.3 12.9 – 15.6 189 14.8 13.7 – 15.9 
 BAP,b µg/L 391 16.1 15.2 – 16.9 125 15.9 14.5 – 17.4 188 16.1 14.9 – 17.2 
 TRAP 5b,b µg/L  392 2.85 2.76 – 2.93 125 2.95 2.80 – 3.10 189 2.87 2.75 – 2.99 
 25(OH)D,c nmol/L 486 44.7 42.6 – 46.8 127 46.5 42.4 – 50.6 279 45.5 42.8 – 48.3 
 PTH,b pg/ml 591 45.7 43.3 – 48.1 168 42.0  37.5 – 46.5 336 46.6 43.5 – 49.8 
Physical function measuresc          
 Timed up and Go, (sec) 739 12.4 11.8 – 13.0 193 11.9 10.8 – 13.0 415 13.7* 12.9 – 14.5 
 IADL 753 25.2 25.0 – 25.5 197 25.2 24.7 – 25.7 424 24.3** 24.0 – 24.7 
 PSM 762 23.3 23.2 – 23.4 200 23.4 23.2 – 23.6 432 23.1* 23.0 – 23.2 
aValues are estimated marginal means (95% CI) adjusted for multiple covariates. Differences in means were assessed by pair-wise comparisons and adjusted for multiple 
comparisons: Bonferroni correction. *,**Different from the lowest milk intake tertile: *P<0.05, **P<0.0001. Non-consumer frequency range (0 – 0.07 units / <once per 
week/never); low consumer frequency range (>0.07- 0.50 units / >once per week to 3-4 times per week); high consumer frequency range (>0.50 – 2.00 units / >3-4 times per 
week to twice per day). 
bAdjusted for age, education, BMI, GFR, physical activity, total daily of yogurt, total daily serving of cheese, calcium or vitamin D supplements (Participants receiving 
medications that could affect bone metabolism were removed from the analysis).                                                       
cAdjusted for age, BMI, total daily serving milk (glass only), total daily serving of cheese; (participants receiving vitamin D supplements were removed from the 25(OH)D 
analysis). Abbreviations: BAP, Bone specific alkaline phosphatase; CTX, C-terminal telopeptides of type I collagen; IADL, Instrumental Activities of Daily Living Scale; OC, 
Osteocalcin; PSM, Physical Self-Maintenance Scale; PTH, Parathyroid hormone; TRAP 5b, Tartrate-resistant acid phosphatase 5b; /d, per day; 25(OH)D, 25-hydroxyvitamin 
D. OC reference range for males of 9.6-40.8 ng/ml and for postmenopausal women 12.8-55.0 ng/ml; CTX reference range is 0.020 ng/mL to 3.380 ng/ml; BAP reference range 
for males of 5.7-32.9 µg/ml and for postmenopausal women 5.5-27.1 µg/ml; TRAP 5b reference range for males of 55-79 ng/ml and for postmenopausal women 41-81 ng/ml; 
Intact PTH measurement range of 1.2 – 5000 pg/ml. and 25(OH)D detection range 7.5-624 nmol/L.                                                                                                                                                                                                                                                                                                                                                                                                       
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